ArticleGigaScience2026
CPSM: an R package for cancer patient survival risk model using transcriptomics and clinical data.
Article in GigaScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CPSM: an R package for cancer patient survival risk model using transcriptomics and clinical data.GigaScience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Traditional Kaplan-Meier curves capture aggregate survival trends within broad patient subgroups but overlook the heterogeneity of individual patients. In contrast, single-patient survival risk models bridge this gap by incorporating each patient's unique clinical, genomic, and demographic characteristics, generating personalized survival curves. These individualized visualizations enhance patient-clinician communication by translating complex statistics into intuitive, time-based visuals that are easier to interpret. However, the complexity, high dimensionality, and heterogeneity of multiomics data present significant challenges for analysis, interpretation, and model development. To address these challenges, we introduce the Cancer Patient Survival Model (CPSM), an R package designed to deliver individualized survival and risk predictions through a fully integrated, reproducible computational pipeline. CPSM includes 10 core functions organized into 4 key steps: (i) data preprocessing and normalization, (ii) feature selection, (iii) survival risk group prediction modeling, and (iv) visualization and nomogram construction. We demonstrate the utility of CPSM using publicly available datasets from The Cancer Genome Atlas for 4 cancer types: glioblastoma multiforme (GBM), acute myeloid leukemia (LAML), pancreatic adenocarcinoma (PAAD), and breast invasive cancer (BRCA). CPSM efficiently handles high-dimensional datasets with over 60,000 RNA transcripts and diverse clinical variables, enabling robust and interpretable individualized survival predictions under varying data conditions. Model performance was evaluated using repeated cross-validation with uncertainty quantification, ensuring robust and reliable estimates in high-dimensional, small-sample settings. In summary, CPSM provides an efficient, user-friendly, end-to-end solution for integrating patient data and generating personalized survival and risk predictions. Its integrated visual tools enhance interpretability and support more informed clinical decision-making. The package is freely available on Bioconductor (https://bioconductor.org/packages/devel/bioc/html/CPSM.html) and GitHub (https://github.com/hks5august/CPSM).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.